# Magnus

> Magnus Medical develops and commercializes SAINT, an FDA-cleared, MRI-guided brain stimulation system for adults with major depressive disorder who have not improved sufficiently with prior antidepressant medication. It combines personalized targeting software with stimulation and neuronavigation hardware, delivered through hospitals and specialist clinics over five treatment days.

- **Founded:** 2020
- **Headquarters:** Burlingame, United States
- **Founders:** Brett Wingeier (Co-founder and founding CEO), Brandon Bentzley (Co-founder and Chief Medical Officer)
- **Products:** SAINT Neuromodulation System, SNT software platform, Verified SAINT Provider support
- **Notable:** FDA Breakthrough Device Designation announced in 2021., FDA 510(k) clearance K220177 issued September 1, 2022., Commercial launch announced April 30, 2024.

## Products & services

- **SAINT Neuromodulation System** — FDA-cleared prescription system combining structural and functional MRI-based targeting, neuronavigation, and accelerated magnetic stimulation for adults with MDD who have not improved sufficiently with prior antidepressant medication in the current episode. Commercially launched April 2024.
- **SNT software platform** — Proprietary neural-network mapping and targeting software supplied to providers as part of the SAINT system; not a separate consumer treatment.
- **Verified SAINT Provider support** — Provider onboarding, training and implementation support for hospitals and specialist treatment sites.

## Achievements

- FDA Breakthrough Device Designation announced in 2021.
- FDA 510(k) clearance K220177 issued September 1, 2022.
- Commercial launch announced April 30, 2024.
- Medicare inpatient New Technology Add-on Payment pathway and subsequent hospital outpatient payment assignments.
- A 2026 replication RCT randomized 48 participants and reported one-month remission of 50.0% with active SNT versus 20.8% with sham.

## Latest updates

- **2026-06** — A multicenter, open-label community study of SAINT effectiveness was published in the Journal of Mood & Anxiety Disorders; its observational design differs from a sham-controlled trial.
- **2026-05** — Magnus reported provider availability in 14 states and expanded payer access covering more than 80 million lives.
- **2026-02** — Magnus announced cease-and-desist letters to companies it believes infringe Stanford-assigned patents; the announcement is an allegation, not a court finding.
- **2026-02** — First patient enrolled at UMass Chan in an approximately $11.6 million DoD-supported postpartum-depression RCT, targeting up to 192 participants.
- **2026-01** — A replication trial published online in World Psychiatry reported 50.0% active versus 20.8% sham remission at one month.
- **2025-12** — Magnus announced preservation of SAINT outpatient APC assignments in the CMS 2026 final rule.

## Links

- Website: https://www.magnusmedical.com/
- LinkedIn: https://www.linkedin.com/company/magnusmedical/
- Twitter/X: https://twitter.com/magnusmed/
- YouTube: https://www.youtube.com/@magnusmedicalinc
- Instagram: https://www.instagram.com/magnusmedicalinc/
- Facebook: https://www.facebook.com/magnusmedicalinc/

---

Profile page: https://yespress.io/magnus
Published by YesPress — https://yespress.io
Last updated: 2026-09-30